Hannah Valantine - 22 Jun 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Director
Issuer ticker: BBIO
Reported as of: 22 Jun 2026
Net transaction value: -$341,524
SEC form: 4
Accepted by SEC: 24 Jun 2026, 18:06:22 UTC
Prior SEC filing: 16 Jun 2026
Next SEC filing: 17 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Will Solis, Attorney-in-Fact

Key filing fact

Hannah Valantine filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 24 Jun 2026.

Key facts

This page summarizes Hannah Valantine's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 24 Jun 2026, 18:06.

Change

Previous filing in this sequence was filed on 16 Jun 2026.
Current net transaction value: -$341,524.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001855608 Primary reporting owner

Valantine Hannah

Relationship: Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Will Solis, Attorney-in-Fact
Signature date: 24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Award

Transaction value
Shares: +3,990
Change %: +53%
Price: $0.000000^*
Shares after: 11,455
Date: 22 Jun 2026
Ownership: Direct
Footnotes: F1, F2

BBIO transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,808
Change %: +25%
Price: $41.73^*
Shares after: 14,263
Date: 22 Jun 2026
Ownership: Direct

BBIO transaction

Common Stock

Sale

Transaction value: $190,944
Shares: -2,808
Change %: -20%
Price: $68.00
Shares after: 11,455
Date: 22 Jun 2026
Ownership: Direct
Footnotes: F3

BBIO transaction

Common Stock

Sale

Transaction value: $150,580
Shares: -2,196
Change %: -19%
Price: $68.57
Shares after: 9,259
Date: 23 Jun 2026
Ownership: Direct
Footnotes: F3

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 398
Date: 22 Jun 2026
Ownership: By Spouse

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,277
Change %
Price: $0.000000^*
Shares after: 5,277
Date: 22 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,277
Exercise price: $68.92
Footnotes: F4

BBIO transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -2,808
Change %: -33%
Price: $0.000000^*
Shares after: 5,617
Date: 22 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,808
Exercise price: $41.73
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.

Footnote F4

The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Footnote F5

One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.